PYC Therapeutics Limited (ASX:PYC)

Australia · Delayed Price · Currency is AUD

1.505

+0.010 (0.67%)

At close: Feb 27, 2026

22.86% (1Y)

Market Cap	1.42B
Revenue (ttm)	20.56M
Net Income (ttm)	-47.56M
Shares Out	941.49M
EPS (ttm)	-0.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	979,514
Average Volume	1,453,188
Open	1.520
Previous Close	1.495
Day's Range	1.490 - 1.525
52-Week Range	0.847 - 1.755
Beta	0.89
RSI	43.72
Earnings Date	Feb 27, 2026

About PYC Therapeutics

PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program, which is in Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for treating blinding eye disease named Autosomal Dominant Optic Atrophy, which is in clinical studies; PYC-002, a drug program for the treatment of severe neurodevelopmental disorder named Phelan-McDermid Syndrome, which ... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2001

Employees 5

Stock Exchange Australian Securities Exchange

Ticker Symbol PYC

Full Company Profile

Financial Performance

In fiscal year 2025, PYC Therapeutics's revenue was 23.49 million, an increase of 6.51% compared to the previous year's 22.06 million. Losses were -50.30 million, 33.3% more than in 2024.

Financial Statements

News

There is no news available yet.